Wen-Li Ma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Wen-Li Ma has a total of 148 co-authors. Here are the top co-authors by number of shared publications:
- Wen-Ling Zheng
Biochemistry and Molecular Biology Director, Institute of Genetic Engineering, Southern Medical University, Guangzhou, 510515, People’s Republic of China
58 shared publications - Yan-Bin Song
Biochemistry and Molecular Biology Director, Institute of Genetic Engineering, Southern Medical University, Guangzhou, 510515, People’s Republic of China
15 shared publications Bao Zhang
12 shared publicationsQing-Hua Wu
12 shared publicationsRong Shi
12 shared publicationsRong Shi
Institute of Genetic Engineering, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China
11 shared publications
Latest Publications
- 23 September 2015
- Published by Spandidos Publications in Oncology Letters
- Vol. 10 (6) , 3619-3624
Reduced expression of sushi domain containing 2 is associated with progression of non-small cell lung cancer
Sushi domain containing 2 (SUSD2) has been identified as a gene encoding an 822-amino acid protein, which contains a transmembrane domain and functional domains inherent to adhesion molecules. Previous studies have reported that increased expression of SUSD2 has a critical role in tumorigenesis in human breast cancer. However, to the best of our knowledge, SUSD2 expression status and its correlation with the clinicopathological features of non‑small cell lung cancer (NSCLC) have not previously been investigated. In the present study, reverse transcription‑quantitative polymerase chain reaction and western blotting were used to evaluate SUSD2 messenger RNA (mRNA) and protein expression in NSCLC and adjacent normal lung tissues. The clinicopathological significance of SUSD2 was investigated by immunohistochemical analysis of an NSCLC tissue microarray. Receiver operating characteristic analysis was used to determine the cut‑off score for positive expression of SUSD2. Furthermore, the correlation between SUSD2 expression and the clinicopathological features of NSCLC was analyzed by χ2 test. The results revealed that SUSD2 mRNA (P<0.0001) and protein (P47.5% (area under ROC curve, 0.799; P<0.000), positive expression of SUSD2 was observed in 100% (32/32) of normal lung tissues and 55% (88/160) of NSCLC tissues by immunohistochemistry (χ2=21.160; P<0.000). Furthermore, it was demonstrated that the reduced SUSD2 protein levels in cancer tissues were positively correlated with poor histological grade (χ2=41.764; P<0.000), advanced clinical stage (χ2=10.790; P=0.013), higher pT (χ2=9.070; P=0.028) and positive regional lymph node metastasis (χ2=15.399; P=0.002). In conclusion, these data suggest that the reduced expression of SUSD2 is associated with the progression of NSCLC and may have a role in the pathogenesis of NSCLC.
- 23 September 2015
- Published by Spandidos Publications in Oncology Letters
- Vol. 10 (6) , 3619-3624
Reduced expression of sushi domain containing 2 is associated with progression of non-small cell lung cancer
Sushi domain containing 2 (SUSD2) has been identified as a gene encoding an 822-amino acid protein, which contains a transmembrane domain and functional domains inherent to adhesion molecules. Previous studies have reported that increased expression of SUSD2 has a critical role in tumorigenesis in human breast cancer. However, to the best of our knowledge, SUSD2 expression status and its correlation with the clinicopathological features of non‑small cell lung cancer (NSCLC) have not previously been investigated. In the present study, reverse transcription‑quantitative polymerase chain reaction and western blotting were used to evaluate SUSD2 messenger RNA (mRNA) and protein expression in NSCLC and adjacent normal lung tissues. The clinicopathological significance of SUSD2 was investigated by immunohistochemical analysis of an NSCLC tissue microarray. Receiver operating characteristic analysis was used to determine the cut‑off score for positive expression of SUSD2. Furthermore, the correlation between SUSD2 expression and the clinicopathological features of NSCLC was analyzed by χ2 test. The results revealed that SUSD2 mRNA (P<0.0001) and protein (P47.5% (area under ROC curve, 0.799; P<0.000), positive expression of SUSD2 was observed in 100% (32/32) of normal lung tissues and 55% (88/160) of NSCLC tissues by immunohistochemistry (χ2=21.160; P<0.000). Furthermore, it was demonstrated that the reduced SUSD2 protein levels in cancer tissues were positively correlated with poor histological grade (χ2=41.764; P<0.000), advanced clinical stage (χ2=10.790; P=0.013), higher pT (χ2=9.070; P=0.028) and positive regional lymph node metastasis (χ2=15.399; P=0.002). In conclusion, these data suggest that the reduced expression of SUSD2 is associated with the progression of NSCLC and may have a role in the pathogenesis of NSCLC.
- Open Access
- 3 June 2015
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 10 (2) , 693-698
Association between hepatitis B virus infection and diabetes mellitus: A meta-analysis
Hepatitis B virus (HBV) infection has been shown by certain studies to be associated with diabetes mellitus (DM); however, the results of these studies were controversial. For that reason, a meta‑analysis of the literature was performed in order to determine the association between HBV infection and the prevalence of DM more accurately. The PubMed, Embase, Chinese National Knowledge Infrastructure and Wan Fang databases, as well as the Chinese Science and Technology Journal Database, were searched for literature published until June 2014. The reference lists of all relevant articles were also searched. The summary odds ratios (ORs) and their corresponding 95% confidence intervals (95% CIs) were calculated based on a random‑effects model. Heterogeneity was assessed using the I2 statistic. Subgroup analyses were conducted based on study type and region for the purpose of assessing the factors that could potentially affect the outcome. A total of 15 eligible studies (in 14 articles) were selected for the meta‑analysis, involving 12,974,690 HBV‑infected patients and 231,776,232 controls. The OR for the prevalence of DM was 1.33 (95% CI, 1.09‑1.62; P=0.005) between the patients with HBV infection and the controls. The subgroup analysis based on study type revealed a significantly higher prevalence of DM in the HBV‑infected group than that in the control group in both case‑control (OR, 1.89; 95% CI, 1.08‑3.30; P=0.025) and cross‑sectional (OR, 1.41; 95% CI, 1.04‑1.90; P=0.027) studies. The subgroup analysis based on region revealed a significantly higher prevalence of DM in the HBV‑infected group than in the control group in the Asia‑Pacific region (OR, 1.67; 95% CI, 1.08‑2.58; P=0.022). Compared with uninfected patients, the pooled results suggest that HBV‑infected patients have a higher risk of developing DM; however, given the fact that this is a meta‑analysis of observational studies, further randomized controlled trials are required in order to reach a more accurate conclusion.
- 3 June 2015
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 10 (2) , 693-698
Open AccessAssociation between hepatitis B virus infection and diabetes mellitus: A meta-analysis
Hepatitis B virus (HBV) infection has been shown by certain studies to be associated with diabetes mellitus (DM); however, the results of these studies were controversial. For that reason, a meta‑analysis of the literature was performed in order to determine the association between HBV infection and the prevalence of DM more accurately. The PubMed, Embase, Chinese National Knowledge Infrastructure and Wan Fang databases, as well as the Chinese Science and Technology Journal Database, were searched for literature published until June 2014. The reference lists of all relevant articles were also searched. The summary odds ratios (ORs) and their corresponding 95% confidence intervals (95% CIs) were calculated based on a random‑effects model. Heterogeneity was assessed using the I2 statistic. Subgroup analyses were conducted based on study type and region for the purpose of assessing the factors that could potentially affect the outcome. A total of 15 eligible studies (in 14 articles) were selected for the meta‑analysis, involving 12,974,690 HBV‑infected patients and 231,776,232 controls. The OR for the prevalence of DM was 1.33 (95% CI, 1.09‑1.62; P=0.005) between the patients with HBV infection and the controls. The subgroup analysis based on study type revealed a significantly higher prevalence of DM in the HBV‑infected group than that in the control group in both case‑control (OR, 1.89; 95% CI, 1.08‑3.30; P=0.025) and cross‑sectional (OR, 1.41; 95% CI, 1.04‑1.90; P=0.027) studies. The subgroup analysis based on region revealed a significantly higher prevalence of DM in the HBV‑infected group than in the control group in the Asia‑Pacific region (OR, 1.67; 95% CI, 1.08‑2.58; P=0.022). Compared with uninfected patients, the pooled results suggest that HBV‑infected patients have a higher risk of developing DM; however, given the fact that this is a meta‑analysis of observational studies, further randomized controlled trials are required in order to reach a more accurate conclusion.
- Open Access
Data mining of Gene expression profiles of Saccharomyces cerevisiae in response to mild heat stress response
We chose yeast as a model organism to explore how eukaryotic cells respond to heat stress. This study provides details on the way yeast responds to temperature changes and is therefore an empirical reference for basic cell research and industrial fermentation of yeast. We use the Qlucore Omics Explorer (QOE) bioinformatics software to analyze the gene expression profiles of the heat stress from Gene Expression Omnibus (GEO). Genes and their expression are listed in heat maps, and the gene function is analyzed against the biological processes and pathways. We can find that the expression of genes changed over time after heat stress. Gene expression changed rapidly from 0 min to 60 min after heat shock, and gene expression stabilized between 60 min to 360 min. The yeast cells begin to adjust themselves to the high temperatures in terms of the level of gene expression at about 60 min. In all of the involved pathways and biological processes, those related to ribosome and nucleic acid metabolism declined in about 15–30 min and those related to starch and sucrose increased in the same time frame. Temperature can be a simple way to control the biological processes and pathways of cell.
Open AccessData mining of Gene expression profiles of Saccharomyces cerevisiae in response to mild heat stress response
We chose yeast as a model organism to explore how eukaryotic cells respond to heat stress. This study provides details on the way yeast responds to temperature changes and is therefore an empirical reference for basic cell research and industrial fermentation of yeast. We use the Qlucore Omics Explorer (QOE) bioinformatics software to analyze the gene expression profiles of the heat stress from Gene Expression Omnibus (GEO). Genes and their expression are listed in heat maps, and the gene function is analyzed against the biological processes and pathways. We can find that the expression of genes changed over time after heat stress. Gene expression changed rapidly from 0 min to 60 min after heat shock, and gene expression stabilized between 60 min to 360 min. The yeast cells begin to adjust themselves to the high temperatures in terms of the level of gene expression at about 60 min. In all of the involved pathways and biological processes, those related to ribosome and nucleic acid metabolism declined in about 15–30 min and those related to starch and sucrose increased in the same time frame. Temperature can be a simple way to control the biological processes and pathways of cell.
- 1 July 2014
- Vol. 34 (8) , 1110-4
[Expression of E3 ligase HERC4 in breast cancer and its clinical implications].
To investigate the expression of HERC4 in human breast cancer tissues and its relationship with the clinicopathological features. RT-qPCR was used to detect mRNA expression of HERC4, and Western blotting and immunohistochemistry were employed to detect protein expression of HERC4 in 67 breast cancer tissues and adjacent breast tissues. The results of RT-qPCR showed a significantly higher mRNA expression of HERC4 in breast cancer tissues than in the adjacent breast tissues (P<0.05). Western blotting demonstrated HERC4 over-expression in breast cancer tissues compared with the adjacent breast tissues (P<0.05). Immunohistochemistry revealed HERC4 expression located predominantly in the cell cytoplasm. Positive HERC4 expression was detected in 61.2% of the breast cancer tissues as compared to 19.4% in the adjacent breast tissues, and its expression level was closely correlated with TNM stage and the histological grade (P<0.05). HERC4 is correlated with the tumorigenesis and progression of breast cancer and may serve as a potential biomarker for early diagnosis and also as a potential therapeutic target in breast cancer.
- 1 July 2014
- Vol. 34 (8) , 1110-4
[Expression of E3 ligase HERC4 in breast cancer and its clinical implications].
To investigate the expression of HERC4 in human breast cancer tissues and its relationship with the clinicopathological features. RT-qPCR was used to detect mRNA expression of HERC4, and Western blotting and immunohistochemistry were employed to detect protein expression of HERC4 in 67 breast cancer tissues and adjacent breast tissues. The results of RT-qPCR showed a significantly higher mRNA expression of HERC4 in breast cancer tissues than in the adjacent breast tissues (P<0.05). Western blotting demonstrated HERC4 over-expression in breast cancer tissues compared with the adjacent breast tissues (P<0.05). Immunohistochemistry revealed HERC4 expression located predominantly in the cell cytoplasm. Positive HERC4 expression was detected in 61.2% of the breast cancer tissues as compared to 19.4% in the adjacent breast tissues, and its expression level was closely correlated with TNM stage and the histological grade (P<0.05). HERC4 is correlated with the tumorigenesis and progression of breast cancer and may serve as a potential biomarker for early diagnosis and also as a potential therapeutic target in breast cancer.
- 28 December 2013
- Published by Springer Nature in Tumor Biology
- Vol. 35 (4) , 3933-3940
Knockdown of CD44 enhances chemosensitivity of acute myeloid leukemia cells to ADM and Ara-C
It is known that chemoresistance is a major cause of treatment failure in acute myeloid leukemia (AML). Substantial data indicate that the CD44 adhesion molecule is strongly expressed on AML blasts and that it can also inhibit apoptosis. Our study shows that drug resistance of the AML cell line HL60/ADM is due to overexpression of CD44. In an in vitro study, we knocked down CD44 in the HL60/ADM cell line using small interfering RNA (siRNA). Cell proliferation and the 50 % inhibitory concentrations (IC50) were determined by Cell Counting Kit-8 (CCK-8) assay. Cell apoptosis and intracellular ADM accumulation were detected by flow cytometry. Expression of CD44, Bcl-2, c-Myc were assayed by quantitative real-time polymerase chain reaction (qRT-PCR) and Western blot. The results indicate that the expression of CD44 in HL60/ADM cell line was much higher than in HL60 cell, and siRNA targeted CD44 (siRNA/CD44) could silence its expression in both mRNA and protein levels effectively. siRNA/CD44 substantially induces cell apoptosis, inhibits cell proliferation, enhances susceptibility to ADM and Ara-C, and at the same time increases intracellular ADM accumulation even reverses chemoresistance to ADM and Ara-C. Furthermore, by qRT-PCR and Western blot, we found that siRNA/CD44 decreases Bcl-2 and c-Myc synthesis. Our study provides a novel clue that CD44 plays a significant role in the chemoresistance of AML cells to Ara-C and ADM. Moreover, this provides a new direction to the approaches that combination therapy including targeting CD44 may overcome drug resistance and improve treatment effects.
- 28 December 2013
- Published by Springer Nature in Tumor Biology
- Vol. 35 (4) , 3933-3940
Knockdown of CD44 enhances chemosensitivity of acute myeloid leukemia cells to ADM and Ara-C
It is known that chemoresistance is a major cause of treatment failure in acute myeloid leukemia (AML). Substantial data indicate that the CD44 adhesion molecule is strongly expressed on AML blasts and that it can also inhibit apoptosis. Our study shows that drug resistance of the AML cell line HL60/ADM is due to overexpression of CD44. In an in vitro study, we knocked down CD44 in the HL60/ADM cell line using small interfering RNA (siRNA). Cell proliferation and the 50 % inhibitory concentrations (IC50) were determined by Cell Counting Kit-8 (CCK-8) assay. Cell apoptosis and intracellular ADM accumulation were detected by flow cytometry. Expression of CD44, Bcl-2, c-Myc were assayed by quantitative real-time polymerase chain reaction (qRT-PCR) and Western blot. The results indicate that the expression of CD44 in HL60/ADM cell line was much higher than in HL60 cell, and siRNA targeted CD44 (siRNA/CD44) could silence its expression in both mRNA and protein levels effectively. siRNA/CD44 substantially induces cell apoptosis, inhibits cell proliferation, enhances susceptibility to ADM and Ara-C, and at the same time increases intracellular ADM accumulation even reverses chemoresistance to ADM and Ara-C. Furthermore, by qRT-PCR and Western blot, we found that siRNA/CD44 decreases Bcl-2 and c-Myc synthesis. Our study provides a novel clue that CD44 plays a significant role in the chemoresistance of AML cells to Ara-C and ADM. Moreover, this provides a new direction to the approaches that combination therapy including targeting CD44 may overcome drug resistance and improve treatment effects.
- 1 October 2013
- Vol. 29 (10) , 1032-5
[Construction and identification of the eukaryotic expression vector expressing short hairpin RNA targeting human COL1A1].
To construct the eukaryotic expression vector of short hairpin RNA (shRNA) targeting human collagen type 1 alpha 1 (COL1A1) and observe its inhibiting effect on the expression of target gene. The complementary oligonucleotide sequences coding shRNA were designed and synthesized according to the sequence of human COL1A1 gene, and cloned into the linearized pSilencer(TM);2.1-U6 neo vector. The recombinant vector was confirmed by enzyme digestion analysis and DNA sequencing, and then the positive clones were transfected to human breast cancer cell MDA-MB-231 by Lipofectamine(TM);2000. The stable cell line was selected by G418. The expression of COL1A1 gene was detected by semi-quantitative RT-PCR and Western blot analysis. Double-enzyme digestion and DNA sequencing verified the correct sequences of the recombinant plasmid pshRNA-COL1A1. Compared with the control group, the expression level of COL1A1 mRNA and protein was inhibited markedly by pshRNA-COL1A1-1 or pshRNA-COL1A1-2 transfection, and the inhibitory rates were respectively (44.41±3.90)%, (63.05±3.13)% in RT-PCR and (45.50±2.71)%, (66.98±2.08)% in Western blot analysis. Specific shRNA interference plasmid vector targeting COL1A1 gene mRNA was constructed successfully.
- 1 October 2013
- Vol. 29 (10) , 1032-5
[Construction and identification of the eukaryotic expression vector expressing short hairpin RNA targeting human COL1A1].
To construct the eukaryotic expression vector of short hairpin RNA (shRNA) targeting human collagen type 1 alpha 1 (COL1A1) and observe its inhibiting effect on the expression of target gene. The complementary oligonucleotide sequences coding shRNA were designed and synthesized according to the sequence of human COL1A1 gene, and cloned into the linearized pSilencer(TM);2.1-U6 neo vector. The recombinant vector was confirmed by enzyme digestion analysis and DNA sequencing, and then the positive clones were transfected to human breast cancer cell MDA-MB-231 by Lipofectamine(TM);2000. The stable cell line was selected by G418. The expression of COL1A1 gene was detected by semi-quantitative RT-PCR and Western blot analysis. Double-enzyme digestion and DNA sequencing verified the correct sequences of the recombinant plasmid pshRNA-COL1A1. Compared with the control group, the expression level of COL1A1 mRNA and protein was inhibited markedly by pshRNA-COL1A1-1 or pshRNA-COL1A1-2 transfection, and the inhibitory rates were respectively (44.41±3.90)%, (63.05±3.13)% in RT-PCR and (45.50±2.71)%, (66.98±2.08)% in Western blot analysis. Specific shRNA interference plasmid vector targeting COL1A1 gene mRNA was constructed successfully.
- 1 September 2013
- Vol. 29 (9) , 931-3
[Construction of eukaryotic expression vector of F-box protein 6 gene and its expression in HEK293T cells].
To construct eukaryotic expression vector of F-box protein 6 (FBXO6) gene. The full-length FBXO6 cDNA containing two restriction sites (BglII and EcoRI) was synthesized by PCR. The pEGFP-C1-FBXO6 and pEGFP-C1-anti-FBXO6 vectors were constructed respectively. The size and sequence of cDNA fragments were confirmed by bacterial colony PCR and BglII and EcoRI digestion and sequencing. HEK293T cells were transfected with the pEGFP-C1-FBXO6 and pEGFP-C1-anti-FBXO6 vectors respectively, and then the expression of FBXO6 protein was detected using Western blotting. The pEGFP-C1-FBXO6 and pEGFP-C1-anti-FBXO6 contained FBXO6 fragments of proper size and sequence. FBXO6 protein was expressed efficiently in pEGFP-C1-FBXO6 transfected HEK293T cells, but it was down-regulated in pEGFP-C1-anti-FBXO6 transfected 293T cells. Both pEGFP-C1-FBXO6 and pEGFP-C1-anti-FBXO6 were successfully constructed.
- 1 September 2013
- Vol. 29 (9) , 931-3
[Construction of eukaryotic expression vector of F-box protein 6 gene and its expression in HEK293T cells].
To construct eukaryotic expression vector of F-box protein 6 (FBXO6) gene. The full-length FBXO6 cDNA containing two restriction sites (BglII and EcoRI) was synthesized by PCR. The pEGFP-C1-FBXO6 and pEGFP-C1-anti-FBXO6 vectors were constructed respectively. The size and sequence of cDNA fragments were confirmed by bacterial colony PCR and BglII and EcoRI digestion and sequencing. HEK293T cells were transfected with the pEGFP-C1-FBXO6 and pEGFP-C1-anti-FBXO6 vectors respectively, and then the expression of FBXO6 protein was detected using Western blotting. The pEGFP-C1-FBXO6 and pEGFP-C1-anti-FBXO6 contained FBXO6 fragments of proper size and sequence. FBXO6 protein was expressed efficiently in pEGFP-C1-FBXO6 transfected HEK293T cells, but it was down-regulated in pEGFP-C1-anti-FBXO6 transfected 293T cells. Both pEGFP-C1-FBXO6 and pEGFP-C1-anti-FBXO6 were successfully constructed.
- 1 December 2012
- Vol. 32 (12) , 1689-94
[Role of aquaporin-1 gene in erythroid differentiation of erythroleukemia K562 cells induced by retinoic acid].
To explore the role of aquaporin-1 (AQP1) gene in erythroid differentiation of erythroleukemia K562 cells induced by retinoic acid (RA). K562 cells were cultured in the presence of 1 µmol/L RA for varying lengths of time, and γ-globin mRNA expression and hemoglobin content in the cells were detected by real-time PCR (RT-PCR) and ultraviolet spectrophotometry, respectively, to evaluate the erythroid differentiation of K562 cells. RT-PCR and Western blotting were used to examine AQP1 expression in the cells following RA treatment. A retroviral expression vector of AQP1 small interfering RNA (pSUPER-retro-puro-shAQP1) was constructed and transfected into K562 cells to establish a K562 cell line with stable AQP1 down-regulation (K562-shAQP1), in which the changes in γ-globin and hemoglobin expressions after RA treatment were detected. RA treatment significantly increased γ-globin and hemoglobin expressions in K562 cells (P<0.01), causing also significantly enhanced AQP1 mRNA and protein expressions over time (P<0.01). Transfection with the recombinant plasmids pSuper-retro-puro-shAQP1 resulted in stable AQP1 suppression in K562 cells (P<0.01), which showed markedly reduced γ-globin and hemoglobin expressions after RA induction as compared to the control K562 cells (P<0.01). K562 cells show a significant increase of AQP1 expression after RA-induced erythroid differentiation, and suppression of AQP1 expression can partially block the effect of RA, suggesting the important role of AQP1 in RA-induced erythroid differentiation of K562 cells.
- 1 December 2012
- Vol. 32 (12) , 1689-94
[Role of aquaporin-1 gene in erythroid differentiation of erythroleukemia K562 cells induced by retinoic acid].
To explore the role of aquaporin-1 (AQP1) gene in erythroid differentiation of erythroleukemia K562 cells induced by retinoic acid (RA). K562 cells were cultured in the presence of 1 µmol/L RA for varying lengths of time, and γ-globin mRNA expression and hemoglobin content in the cells were detected by real-time PCR (RT-PCR) and ultraviolet spectrophotometry, respectively, to evaluate the erythroid differentiation of K562 cells. RT-PCR and Western blotting were used to examine AQP1 expression in the cells following RA treatment. A retroviral expression vector of AQP1 small interfering RNA (pSUPER-retro-puro-shAQP1) was constructed and transfected into K562 cells to establish a K562 cell line with stable AQP1 down-regulation (K562-shAQP1), in which the changes in γ-globin and hemoglobin expressions after RA treatment were detected. RA treatment significantly increased γ-globin and hemoglobin expressions in K562 cells (P<0.01), causing also significantly enhanced AQP1 mRNA and protein expressions over time (P<0.01). Transfection with the recombinant plasmids pSuper-retro-puro-shAQP1 resulted in stable AQP1 suppression in K562 cells (P<0.01), which showed markedly reduced γ-globin and hemoglobin expressions after RA induction as compared to the control K562 cells (P<0.01). K562 cells show a significant increase of AQP1 expression after RA-induced erythroid differentiation, and suppression of AQP1 expression can partially block the effect of RA, suggesting the important role of AQP1 in RA-induced erythroid differentiation of K562 cells.
- 23 November 2012
- Published by Springer Nature in Tumor Biology
- Vol. 34 (2) , 629-636
Overexpression of amyloid precursor protein in acute myeloid leukemia enhances extramedullary infiltration by MMP-2
It is known that leukemia patients with extramedullary infiltration (EMI) have a worse prognosis than patients without it. Recent data indicate that the amyloid precursor protein (APP) is involved in cell adhesion, motility, and proliferation. The expression of APP and its prognostic significance in acute myeloid leukemia (AML) have not been studied. Our study shows that AML/ETO+ leukemia patients that overexpress APP easily get EMI and that their long-term survival rate is lower than patients without overexpression of APP. In an in vitro study, we knocked down APP in Kasumi-1 cells using small interfering RNA (siRNA). Transwell data show that siRNA/APP substantially impairs cell migration, but it does not inhibit cell proliferation. Furthermore, by quantitative real-time polymerase chain reaction and Western blot, we found that siRNA/APP decreases MMP-2 expression in vitro. Our study provides a novel clue that APP is involved in the extramedullary infiltration of leukemia by MMP-2.
- 23 November 2012
- Published by Springer Nature in Tumor Biology
- Vol. 34 (2) , 629-636
Overexpression of amyloid precursor protein in acute myeloid leukemia enhances extramedullary infiltration by MMP-2
It is known that leukemia patients with extramedullary infiltration (EMI) have a worse prognosis than patients without it. Recent data indicate that the amyloid precursor protein (APP) is involved in cell adhesion, motility, and proliferation. The expression of APP and its prognostic significance in acute myeloid leukemia (AML) have not been studied. Our study shows that AML/ETO+ leukemia patients that overexpress APP easily get EMI and that their long-term survival rate is lower than patients without overexpression of APP. In an in vitro study, we knocked down APP in Kasumi-1 cells using small interfering RNA (siRNA). Transwell data show that siRNA/APP substantially impairs cell migration, but it does not inhibit cell proliferation. Furthermore, by quantitative real-time polymerase chain reaction and Western blot, we found that siRNA/APP decreases MMP-2 expression in vitro. Our study provides a novel clue that APP is involved in the extramedullary infiltration of leukemia by MMP-2.
- 18 October 2012
- Published by Spandidos Publications in Molecular and Clinical Oncology
- Vol. 1 (2) , 215-219
Deguelin, a novel anti-tumorigenic agent targeting apoptosis, cell cycle arrest and anti-angiogenesis for cancer chemoprevention
Deguelin is a natural compound of the flavonoid family products isolated from Derris trifoliata Lour. or Mundulea sericea (Leguminosae). It exhibited significant anti-tumorigenesis and anti-proliferative activity in various types of cancer both in vitro and in vivo. Deguelin induced cell apoptosis by blocking anti-apoptotic pathways, such as PI3K-Akt, IKK-IκBα-NF-κB and AMPK-mTOR-survivin, while inhibiting tumor cell propagation and malignant transformation through p27-cyclinE-pRb-E2F1 cell cycle control and HIF-1α-VEGF anti-angiogenic pathways. In pre-clinical trials, deguelin markedly decreased the tumor incidence. These biological findings identified deguelin as a novel anti-tumorigenic agent targeting apoptosis, cell cycle arrest and anti-angiogenesis for cancer chemoprevention and chemotherapy.
- 18 October 2012
- Published by Spandidos Publications in Molecular and Clinical Oncology
- Vol. 1 (2) , 215-219
Deguelin, a novel anti-tumorigenic agent targeting apoptosis, cell cycle arrest and anti-angiogenesis for cancer chemoprevention
Deguelin is a natural compound of the flavonoid family products isolated from Derris trifoliata Lour. or Mundulea sericea (Leguminosae). It exhibited significant anti-tumorigenesis and anti-proliferative activity in various types of cancer both in vitro and in vivo. Deguelin induced cell apoptosis by blocking anti-apoptotic pathways, such as PI3K-Akt, IKK-IκBα-NF-κB and AMPK-mTOR-survivin, while inhibiting tumor cell propagation and malignant transformation through p27-cyclinE-pRb-E2F1 cell cycle control and HIF-1α-VEGF anti-angiogenic pathways. In pre-clinical trials, deguelin markedly decreased the tumor incidence. These biological findings identified deguelin as a novel anti-tumorigenic agent targeting apoptosis, cell cycle arrest and anti-angiogenesis for cancer chemoprevention and chemotherapy.